Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Launched by ROSWELL PARK CANCER INSTITUTE · May 23, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with metastatic or inoperable locally advanced triple-negative breast cancer, which is a type of breast cancer that does not respond to certain hormones. The study is testing two medications, tamoxifen and pegylated liposomal doxorubicin, to see if using them together can be more effective than using either one alone. Tamoxifen works by blocking the effects of estrogen, which some cancer cells need to grow, while liposomal doxorubicin is designed to deliver cancer-fighting medication more effectively and with potentially fewer side effects.

To be eligible for this trial, participants must be at least 18 years old and have confirmed triple-negative breast cancer that has already been treated with at least two other therapies. They must also meet certain health criteria, such as having a specific level of blood cells and proper liver function. Those interested in joining the study will need to understand the purpose of the trial and provide written consent before starting any study-related procedures. Overall, this trial aims to find out if this combination treatment can improve outcomes for patients facing a challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with pathologically confirmed metastatic triple negative breast cancer (ER ≤ 10%) that have been previously treated with at least 2 lines of therapy in the metastatic setting
• • Patients must have ERα (estrogen receptor alpha) and PgR (progesterone receptor) status assessed using current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Patients are eligible if the tumor staining is ERα low/negative (ER ≤ 10%) and PgR negative by ASCO/CAP guidelines
• • The tumor must be HER-2 negative by immunochemistry (IHC) 0-1+ or IHC 2 + and fluorescence in situ hybridization (FISH) negative
• • Patients must be ≥ 18 years of age
• • Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• • Absolute neutrophil count (ANC) ≥ 1500/ μL
• • Hemoglobulin (hb) ≥ 9 g/dL
• • Platelet count ≥ 100,000/ μL
• • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
• • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2 x ULN
• • Creatinine clearance \> 60 mL/min (Cockroft-Gault Equation)
• • Left ventricular ejection fraction (LVEF) assessment must be performed within 30 days prior to enrollment. (LVEF assessment performed by 2-D echocardiogram is preferred; however, multigated acquisition scan \[MUGA\] scan may be substituted based on institutional preferences). The LVEF must be ≥ 50% regardless of the cardiac imaging facility's lower limit of normal
• • Patients must be able to swallow oral medications
• • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
• Exclusion Criteria:
• • Patients must not have any known contraindications to endocrine therapy, in the opinion of the treating investigator
• • Participants who have had chemotherapy, hormonal/endocrine therapy, immunotherapy, biologics or radiotherapy (as well as any other investigational agents/devices) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• • Have a known history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to tamoxifen or any of its excipients
• • Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary embolism
• • Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness
• • Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimen. This includes angina pectoris, arrhythmias except for benign premature ventricular contractions, a history of myocardial infarction, documented congestive heart failure (CHF) or cardiomyopathy
• • Patients with cirrhosis or severe hepatic impairment
• • Patients must not have a condition or an uncontrolled intercurrent illness including, but not limited to any of the following: ongoing or active infection requiring systemic treatment, except uncomplicated urinary tract infection (UTI), or psychiatric illness/social situations that would limit compliance with study requirements
• • Pregnant or nursing female participants
• • Unwilling or unable to follow protocol requirements
• • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug